Sesen Bio Inc (SESN)

4.54 +0.28  +6.57% NASDAQ Jun 17, 15:43 USD
View Full Chart
Price Chart
View All SESN News

News

View All Events

Events

Date Type Description
11/09/2021 08:00 EST Earnings Calls Q3 2021 Earnings Call
08/10/2021 Earnings Results Q2 2021 Earnings Results
05/10/2021 Earnings Results Q1 2021 Earnings Results
05/10/2021 08:00 EST Earnings Calls Q1 2021 Earnings Call
05/03/2021 08:00 EST AGM 2020 Annual General Meeting
03/15/2021 Earnings Results Q4 2020 Earnings Results
03/15/2021 08:00 EST Earnings Calls Q4 2020 Earnings Call
11/09/2020 Earnings Results Q3 2020 Earnings Results
11/09/2020 08:00 EST Earnings Calls Q3 2020 Earnings Call
08/10/2020 Earnings Results Q2 2020 Earnings Results
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • Description: Sesen Bio Inc is a late-stage clinical company engaged in next-generation antibody-drug conjugate therapies for the treatment of cancer-based on the company's Targeted Protein Therapeutics platform. The company's lead program, Vicinium, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of BCG-unresponsive NMIBC.
  • URL: https://www.sesenbio.com
  • Investor Relations URL: N/A
  • HQ State/Province: Massachusetts
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Small Cap/Value
  • Next Earnings Release: Aug. 10, 2021
  • Last Earnings Release: May. 10, 2021
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.